Evidence map›Paper›PMID 40813133›Full record

ArticleEpidemiology and infection2025

Multiplex RT-qPCR strategy for SARS-CoV-2 variants detection in developing countries without ngs: The Bolivian experience.

Rudy Parrado, Carolina X Cuba-Grandy, Eugenia Fuentes-Luppichini, Nattaly Grecia Torrico Villarroel, Yercin Mamani-Ortiz, Jaqueline Mendez, Betty Melgarejo, Irenice Coronado-Arrázola, Nair A Montaño, Leonardo I Almonacid and 3 more

Abstract read
In one paragraph

Article in Epidemiology and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rudy ParradoInstituto de Investigaciones Biomédicas (IIBISMED), Universidad Mayor de San Simón, Cochabamba, Bolivia.
Carolina X Cuba-GrandyInstituto de Investigaciones Biomédicas (IIBISMED), Universidad Mayor de San Simón, Cochabamba, Bolivia.
Eugenia Fuentes-LuppichiniDepartment of Pediatric Infectious Diseases and Immunology, School of Medicine, https://ror.org/04teye511Pontificia Universidad Católica de Chile, Santiago, Chile.
Nattaly Grecia Torrico VillarroelFacultad de Ciencias Farmacéuticas y Bioquímicas, https://ror.org/03z27es23Universidad Mayor de San Simón, Cochabamba, Bolivia.
Yercin Mamani-OrtizInstituto de Investigaciones Biomédicas (IIBISMED), Universidad Mayor de San Simón, Cochabamba, Bolivia.
Jaqueline MendezDepartmental Health Service of Cochabamba, Cochabamba, Bolivia.
Betty MelgarejoDepartmental Health Service of Cochabamba, Cochabamba, Bolivia.
Irenice Coronado-ArrázolaInstituto de Investigaciones Biomédicas (IIBISMED), Universidad Mayor de San Simón, Cochabamba, Bolivia.
Nair A MontañoInstituto de Investigaciones Biomédicas (IIBISMED), Universidad Mayor de San Simón, Cochabamba, Bolivia.
Leonardo I AlmonacidMolecular Bioinformatics Laboratory, Department of Molecular Genetics and Microbiology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile.
Rafael A MedinaDepartment of Pediatric Infectious Diseases and Immunology, School of Medicine, https://ror.org/04teye511Pontificia Universidad Católica de Chile, Santiago, Chile.
Lineth GarciaInstituto de Investigaciones Biomédicas (IIBISMED), Universidad Mayor de San Simón, Cochabamba, Bolivia.
Catalina Pardo-RoaDepartment of Pediatric Infectious Diseases and Immunology, School of Medicine, https://ror.org/04teye511Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID 0000-0002-5409-225X

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Fondo Nacional de Desarrollo Científico y Tecnológico 11231122National Institute of Allergy and Infectious Diseases CEIRS, contract # HHSN272201400008C,CRIP, Contrat No. 75N93021C00014NIAID NIH HHS 75N93021C00014NIAID NIH HHS HHSN272201400008CPontificia Universidad Católica de Chile PIA-UC
6 · The paper itself

Abstract

The rapid evolution of SARS-CoV-2 has led to the emergence of variants of concern (VOCs) characterized by increased transmissibility, pathogenicity, and resistance to neutralizing antibodies. Identifying these variants is essential for guiding public health efforts to control COVID-19. Although whole genome sequencing (WGS) is the gold standard for variant identification, its implementation is often limited in developing countries due to resource constraints. In Bolivia, genomic surveillance is a challenge due to its limited technological infrastructure and resources. An RT-qPCR-based strategy was designed to address these limitations and detect the mutations associated with VOCs and variants of interest (VOIs). The multiplex RT-qPCR commercial kits Allplex

Indexed as

COVID-19COVID-19 Nucleic Acid TestingMultiplex Polymerase Chain ReactionReal-Time Polymerase Chain ReactionSARS-CoV-2BoliviaDeveloping CountriesHumansMutation

Identifiers

PMID40813133
PMCPMC12394009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.